Clinical Observation of Recombinant Bovine Basic Fibroblast Growth Factor Eye Gel Combined with Tobramycin Dexamethasone Eye Drops in the Treatment of Dry Eye Syndrome in Patients after Cataract Surgery

Objective: To evaluate the therapeutic effect of recombinant bovine basic fibroblast growth factor (rbFGF) eye gel combined with tobramycin-dexamethasone (TOB-Dex) eye drops on dry eye syndrome (DES) after cataract surgery. Methods: 86 patients with DES after cataract surgery, admitted from November 2021 to November 2023, were randomly divided into groups. The observation group included 43 patients treated with rbFGF eye gel combined with TOB-Dex eye drops. The reference group included 43 patients treated with TOB-Dex eye drops alone. Multiple indicators, including total effective rate and clinical symptom scores, were compared between the two groups. Results: The total effective rate in the observation group was higher than in the reference group (P < 0.05). Before treatment, there were no differences in clinical symptom scores, serum factors, or disease severity scores between the two groups (P > 0.05). Three weeks after treatment, the observation group had lower clinical symptom scores, serum factors, and disease severity scores compared to the reference group (P < 0.05). The adverse reaction rate in the observation group was lower than in the reference group (P < 0.05). Conclusion: rbFGF eye gel combined with TOB-Dex eye drops can improve the clinical efficacy for patients with DES after cataract surgery, alleviate disease symptoms, reduce inflammatory responses, and have fewer adverse reactions.